Unfortunately, the advantage of proposing this new abnormal body composition phenotype introduces challenges to future research endeavors. Primarily, it leads to additional debate on the diagnosis of osteosarcopenic obesity, which in turn can impact risk prediction and treatment strategies. Although the definition of osteopenia/osteoporosis has been quite widely accepted, substantial debate still exists regarding the definition of sarcopenia and even obesity [21]. Likewise, the expected prevalence of osteosarcopenic obesity in the general population is uncertain. The combination of three diagnostic criteria (for abnormal bone, muscle, and fat) may limit the number of individuals presenting with this condition, which will impact the identification of this phenotype in non-epidemiological studies in healthy populations. On the contrary, we hypothesize that the prevalence of osteosarcopenic obesity will be pronounced in those presenting with clinical conditions (e.g., cancer, diabetes, etc.).